Evidence map›Paper›PMID 41979909›Full record

ArticleBiochimica et biophysica acta. General subjects2026

Selection and evaluation of new sites for splitting beta-lactamase to modulate auto-complementation enzyme activity.

Morgan C Marsh, Shawn C Owen

Abstract read
In one paragraph

Article in Biochimica et biophysica acta. General subjects, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Morgan C MarshDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, United States of America.
Shawn C OwenDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, United States of America; Department of Medicinal Chemistry, Department of Biomedical Engineering, University of Utah, United States of America. Electronic address: shawn.owen@hsc.utah.edu.

Funding

Binding-Induced Enzyme Activation for Prodrug Therapy of HER2 VariantsR01EB038025 · NIBIB · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Shawn C Owen · 2025 to 2026
$678k
NIBIB NIH HHS R01 EB038025
6 · The paper itself

Abstract

Split protein systems, including split fluorescent proteins and split enzymes, have predominantly been applied to monitor protein-protein interactions but have recently gained popularity as components in induced complementation diagnostic platforms. Many of these systems are limited by self-affinity which limits the dynamics or causes a false-positive high background signal. To overcome these challenges, it is necessary to either modify the interacting residues of established split fragments or by exploring new split-sites. Using the computational modeling tool SPELL to identify stable candidates, we developed five unique split sites for TEM-1 β-lactamase to compare structure and activity versus the original split site. We monitored structural changes through MMS IR spectroscopy as well as functional activity of each split enzyme. Expected structural changes of each fragment and changes in self-affinity driven complementation were observed. By utilizing specific binding proteins attached to the split enzyme, we monitored enzyme activity with forced complementation when bound to the target compared to auto-complementation when the enzymes were auto-complexed in solution. Of the five new split sites, one maintained high binding-mediated complementation activity with significant reduction in background auto-complementation. Changing the split site is a relatively simple approach to reduce background activity while maintaining on-target activity. The ability to tune split-systems has the potential to enable more sensitive and complex studies that previously were limited by the high background from self-affinity.

Indexed as

beta-LactamasesBinding SitesEscherichia coliModels, MolecularProtein Bindingbeta-Lactamasesbeta-lactamase TEM-1AffinityProtein engineeringSecondary structureSplit-enzyme

Identifiers

PMID41979909
PMCPMC13080209

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.